Roche Clinical trial

Roche and Genentech (the US member of the Roche group) have now recruited their first patient for the “Tangelo” clinical trial which is a Phase 1 open-label trial to investigate the safety, tolerability, pharmacokinetics & pharmacodynamics of RO7248824.   The study will recruit 66 individuals with either a mutation or deletion between the ages of one and twelve years.

https://forpatients.roche.com/en/trials/neurodevelopmental-disorder/angelman-syndrome/a-study-to-investigate-the-safety–tolerability–pharma-19556.html

Share
Share on facebook
Facebook
Share on linkedin
LinkedIn
Share on email
Email